Emmaus Life Sciences Inc
OTC:EMMA

Watchlist Manager
Emmaus Life Sciences Inc Logo
Emmaus Life Sciences Inc
OTC:EMMA
Watchlist
Price: 0.013 USD Market Closed
Market Cap: 830.3k USD

Emmaus Life Sciences Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Emmaus Life Sciences Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Emmaus Life Sciences Inc
OTC:EMMA
EPS (Diluted)
$0
CAGR 3-Years
33%
CAGR 5-Years
25%
CAGR 10-Years
45%
Johnson & Johnson
NYSE:JNJ
EPS (Diluted)
$10
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
EPS (Diluted)
$2
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
EPS (Diluted)
$1
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
EPS (Diluted)
$7
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
EPS (Diluted)
$20
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
25%
No Stocks Found

Emmaus Life Sciences Inc
Glance View

Market Cap
830.3k USD
Industry
Pharmaceuticals

Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.

EMMA Intrinsic Value
Not Available

See Also

What is Emmaus Life Sciences Inc's EPS (Diluted)?
EPS (Diluted)
-0.1 USD

Based on the financial report for Sep 30, 2025, Emmaus Life Sciences Inc's EPS (Diluted) amounts to -0.1 USD.

What is Emmaus Life Sciences Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
45%

Over the last year, the EPS (Diluted) growth was -450%. The average annual EPS (Diluted) growth rates for Emmaus Life Sciences Inc have been 33% over the past three years , 25% over the past five years , and 45% over the past ten years .

Back to Top